GSK announced Thursday that it has begun shipping its influenza vaccines to the United States for the season starting this fall and ending next year.

Following U.S. FDA approval, GSK plans to supply some 36 million doses of its trivalent influenza A and B vaccines Flulaval and Fluarix, for adults and children over six months of age, to health centers and pharmacies nationwide.

The CDC estimates that during the last season, which ran from October 2023 to June 2024, between 35 and 65 million Americans were affected by influenza, resulting in between 390,000 and 830,000 hospitalizations and between 25,000 and 72,000 deaths.

Copyright (c) 2024 CercleFinance.com. All rights reserved.